BofA raised the firm’s price target on Encompass Health (EHC) to $128 from $125 and keeps a Buy rating on the shares. With “another beat and guidance raise,” the Encompass “story is on track,” the analyst tells investors. Given Encompass’ historical conservatism, the firm expects guidance will keep moving higher through the year, adds the analsyt, who raised the firm’s estimates for the beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health price target raised to $122 from $120 at KeyBanc
- Encompass Health price target raised to $129 from $118 at Barclays
- Encompass Health: Strong Financial Performance and Resilient Growth Justify Buy Rating
- Encompass Health Appoints New COO Patrick W. Tuer
- Encompass Health names Patrick Tuer as COO, effective immediately